2seventy Bio, Inc. and Bristol Myers Squibb Company have hit a snag in efforts to expand the market reach of the CAR-T cell therapy Abecma (idecabtagene vicleucel) as the companies had to stop a Phase III trial of the cell therapy due to shifts in how multiple myeloma is treated.
2seventy said 25 September that it would discontinue enrollment of the KarMMa-9 trial of the BCMA-directed cell therapy as a maintenance therapy combined with lenalidomide (BMS’s Revlimid and generics) versus lenalidomide alone in newly diagnosed multiple
Key Takeaways
-
2seventy bio and BMS will stop enrollment in the KarMMa-9 trial due to evolution of the treatment landscape.
-
Increasing use of quadruplet therapy induction as well as other changes in the treatment paradigm have resulted in considerably fewer eligible patients being available than when the trial started
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?